Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.

Abstract

This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.

• Authors: Enriqueta Albizua, Miguel Gallardo, Santiago Barrio, Inmaculada Rapado, Ana Jimenez, Rosa Ayala, Daniel Rueda, Beatriz Sanchez-Espiridion, Eulalia Puigdecanet, Blanca Espinet, Lourdes Florensa, Carles Besses, Joaquin Martinez-Lopez
• Journal: Annals of hematology (Ann Hematol) Vol. 90 Issue 8 Pg. 939-46 (Aug 2011) ISSN: 1432-0584 [Electronic] Germany
• PMID: 21331593 (Publication Type: Journal Article)

Chemical References

• Transcription Factors
• JAK2 protein, human
• Janus Kinase 2
• src-Family Kinases
• Hydroxyurea

Topics

• Adult
• Aged
• Aged, 80 and over
• Case-Control Studies
• Female
• Gene Expression Profiling
• Gene Expression Regulation (drug effects)
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Hydroxyurea (pharmacology, therapeutic use)
• Janus Kinase 2 (genetics)
• Male
• Middle Aged
• Polycythemia (drug therapy, genetics)
• Polycythemia Vera (drug therapy, genetics)
• Signal Transduction (drug effects, genetics)
• Thrombocythemia, Essential (drug therapy, genetics)
• Transcription Factors (drug effects, genetics)
• Young Adult
• src-Family Kinases (genetics)